Information Provided By:
Fly News Breaks for March 26, 2019
Mar 26, 2019 | 08:52 EDT
JMP Securities analyst Liisa Bayko said Aimmune's "strong" efficacy and safety data from the Phase 3 ARTEMIS study sets the stage for a marketing authorization application to the European Medicines Agency in mid-2019. The analyst, who assigns a 90% probability of success for AR101 in peanut allergy, keeps an Outperform rating and $40 price target on Aimmune shares.
News For AIMT From the Last 2 Days
There are no results for your query AIMT